Scolaris Content Display Scolaris Content Display

برنامه‌‌های سرسوزن سرنگ و درمان جایگزینی اوپیوئید برای پیشگیری از انتقال هپاتیت C در افرادی که مواد مخدر تزریق می‌‌کنند

Appendices

Appendix 1. Search strategies to identify studies that measure the impact of NSP/OST on HCV incidence

Cochrane Drug and Alcohol Group Specialised Register (CRS)

  1. (HCV) AND (INREGISTER)

  2. ("hepatitis C") AND (INREGISTER)

  3. ("hep C") AND (INREGISTER)

  4. #1 OR #2 OR #3

CENTRAL, DARE, NHSEED and HTA (Cochrane Library)

  1. MeSH descriptor: [Needle‐Exchange Programs] explode all trees

  2. MeSH descriptor: [Community Pharmacy Services] explode all trees

  3. ((needle* or syringe* or inject*) near/3 exchange):ti,ab,kw (Word variations have been searched)

  4. MeSH descriptor: [Harm Reduction] explode all trees

  5. (harm near/2 reduc*):ti,ab,kw (Word variations have been searched)

  6. (needle* or syringe* or inject*) near/3 (suppl* or access* or provision or provid* or distribut* or dispens* or pack*):ti,ab,kw (Word variations have been searched)

  7. (needle* or syringe* or inject*) near/3 (program* or service* or center* or centre* or scheme* or facility or facilities or area* or pharmacy or pharmacies or unit or units or room*):ti,ab,kw (Word variations have been searched)

  8. (needle* or syringe* or inject* or slot or dispensing or vending) near/3 (machine* or (peer next distrib*)):ti,ab,kw (Word variations have been searched)

  9. #1 or #2 or #3 or #4 or #5 or #5 or #6 or #7 or #8

  10. MeSH descriptor: [Substance Abuse, Intravenous] explode all trees

  11. ((substance* or drug* or opiate* or opioid* or heroin* or morphin* or morfin* or narcot*) near/6 (use* or abus* or misuse* or addict* or depend*)):ti,ab,kw (Word variations have been searched)

  12. (substance* or drug) and (inject* or intravenous):ti,ab,kw (Word variations have been searched)

  13. #10 or #11 or #12

  14. MeSH descriptor: [Opiate Substitution Treatment] explode all trees

  15. MeSH descriptor: [Methadone] explode all trees

  16. MeSH descriptor: [Buprenorphine] explode all trees

  17. (substitut* or maint*) near/2 (treatment or therapy):ti,ab,kw (Word variations have been searched)

  18. (methadone or buprenorphine or subutex or suboxone):ti,ab,kw (Word variations have been searched)

  19. #13 or #14 or #15 or #16 or #17 or #18

  20. #9 or #19

  21. MeSH descriptor: [Hepatitis C] explode all trees

  22. (hepatitis next C) or (hep next C):ti,ab,kw (Word variations have been searched)

  23. HCV:ti,ab

  24. #21 or #22 or #23

  25. #13 and #20 and #24

MEDLINE, PsycINFO and Global Health (Ovid)

  1. Needle‐Exchange Programs/

  2. Community pharmacy services/

  3. ((needle* or syringe* or inject*) adj3 exchange).ab,ti.

  4. Harm Reduction/

  5. (harm adj reduc*).ab,ti.

  6. ((needle* or syringe* or inject*) adj3 (suppl* or access* or provision or provid* or distribut* or dispens* or pack*)).ab,ti.

  7. ((needle* or syringe* or inject*) adj3 (program* or service* or center* or centre* or scheme* or facility or facilities or area* or pharmacy or pharmacies or unit or units or room*)).ab,ti.

  8. ((needle* or syringe* or inject* or slot or dispensing or vending) adj3 (machine* or (peer adj distrib*))).ab,ti.

  9. or/1‐8

  10. Substance Abuse, Intravenous/

  11. (substance$ or drug$).ab,ti.

  12. (abuse$ or depend$ or use$ or misus$ or addict$).ab,ti.

  13. (inject$ or intravenous).ab,ti.

  14. 10 or (11 and 12) or (11 and 13)

  15. opiate substitution treatment/

  16. methadone/

  17. buprenorphine/

  18. (((substitut* or maint*) adj2 (treatment or therapy)) or methadone or buprenorphine or subutex or suboxone).ab,ti.

  19. or/15‐18

  20. exp Hepatitis C/

  21. (hepatitis‐c or or hep c or hcv).ab,ti.

  22. 20 or 21

  23. (9 or 19) and 14 and 22

EMBASE (embase.com)

'substance abuse'/exp OR 'substance abuse' OR ((substance* OR drug* OR opiate* OR opioid* OR heroin* OR morphin* OR morfin* OR narcot*) NEAR/6 (use* OR abus* OR misuse* OR addict* OR depend*)):ab,ti OR ((substance* OR drug*) NEAR/6 (inject* OR intravenous)):ab,ti AND ('hepatitis c'/exp OR 'hepatitis‐c':ab,ti OR 'hep c':ab,ti OR hcv:ab,ti) AND ('preventive health service'/exp OR ((needle* OR syringe* OR inject*) NEAR/3 exchange):ab,ti OR 'harm reduction'/exp OR (harm NEAR/2 reduc*):ab,ti OR ((needle* OR syringe* OR inject*) NEAR/3 (suppl* OR access* OR provision OR provid* OR distribut* OR dispens* OR pack*)):ab,ti OR ((needle* OR syringe* OR inject*) NEAR/3 (program* OR service* OR center* OR centre* OR scheme* OR facility OR facilities OR area* OR pharmacy OR pharmacies OR unit OR units OR room*)):ab,ti OR ((needle* OR syringe* OR inject* OR slot OR dispensing OR vending) NEAR/3 (machine* OR peer)):ab,ti OR 'opiate substitution treatment'/exp OR 'methadone'/exp OR methadone:ab,ti OR 'buprenorphine'/exp OR 'buprenorphine':ab,ti OR ((substitut* OR maint*) NEAR/2 (treatment OR therapy)):ab,ti OR subutex:ab,ti OR suboxone:ab,ti)

CINAHL (EBSCO)

  1. (MH "Needle Exchange Programs")

  2. TI((needle* OR syringe*OR inject*) N3 exchange) OR AB(needle* OR syringe* OR inject*) N3 exchange)

  3. (MH "Harm Reduction")

  4. TI (harm N2 reduc*) OR AB (harm N2 reduc*)

  5. TI ((needle* OR syringe* OR inject*) N3 (suppl* OR access* OR provision OR provid* OR distribut* OR dispens* OR pack*) ) OR AB ( TI(needle* OR syringe* OR inject*) N3 (suppl* OR access* OR provision OR provid* OR distribut* OR dispens* OR pack*))

  6. TI ((needle* OR syringe* OR inject*) N3 (program* OR service* OR center* OR centre* OR scheme* OR facility OR facilities OR area* OR pharmacy OR pharmacies OR unit OR units OR room*)) OR AB ( (needle* OR syringe* OR inject*) N3 (program* OR service* OR center* OR centre* OR scheme* OR facility or facilities OR area* OR pharmacy OR pharmacies OR unit OR units OR room*))

  7. TI (((needle* OR syringe* OR inject* OR slot OR dispensing OR vending) N3 (machine*OR (peer N2 distrib*)))) OR AB ( ((needle* OR syringe* OR inject* OR slot OR dispensing OR vending) N3 (machine* OR (peer N2 distrib*))))

  8. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7

  9. (MH "Substance Abuse, Intravenous")

  10. TI ((substance* OR drug* OR opiate* OR opioid* OR heroin* OR morphin* OR morfin* OR narcot*) N6 (use* OR abus* OR misuse* OR addict* OR depend*))

  11. AB ((substance* OR drug* OR opiate* OR opioid* OR heroin* OR morphin* OR morfin* OR narcot*) N6 (use* OR abus* OR misuse* OR addict* ORdepend*))

  12. TI (substance* OR drug*) AND TI (inject* OR intravenous)

  13. AB(substance* OR drug* ) AND AB( inject* OR intravenous)

  14. S9 OR S10 OR S11 OR S12 OR S13

  15. (MH "Methadone") OR (MH "Buprenorphine")

  16. TI (methadone or buprenorphine or subutex or suboxone) OR AB (methadone or buprenorphine or subutex or suboxone)

  17. TX (substitut* or maint*) N2 (treatment or therapy)

  18. S15 OR S16 OR S17

  19. (MH "Hepatitis C+")

  20. TI ( "hepatitis‐c" or "hep c" or hcv ) OR AB ( "hepatitis‐c" or "hep c" or hcv )

  21. S19 OR S20

  22. S8 OR S18

  23. S14 AND S21 AND S22

Web of Science (THOMSON REUTERS)

  1. TOPIC: (((needle* OR syringe* OR inject*) NEAR/3 exchange))

  2. TOPIC: (harm NEAR/2 reduc*)

  3. TOPIC: (((needle* OR syringe* OR inject*) NEAR/3 (suppl* OR access* OR provision OR provid* OR distribut* OR dispens* OR pack*)))

  4. TOPIC: ((needle* or syringe* or inject*) near/3 (program* or service* or center* or centre* or scheme* or facility or facilities or area* or pharmacy or pharmacies or unit or units or room*))

  5. TOPIC: ((needle* or syringe* or inject* or slot or dispensing or vending) NEAR/3 (machine* orpeer))

  6. #5 OR #4 OR #3 OR #2 OR #1

  7. TOPIC: (((substance* OR drug* OR opiate* OR opioid* OR heroin* OR morphin* OR morfin* OR narcot*) NEAR/6 (use* OR abus* OR misuse* OR addict* OR depend*)))

  8. TOPIC: ((substance* or drug) and (inject* or intravenous))

  9. #8 OR #7

  10. TOPIC: ((substitut* or maint*) near/2 (treatment or therapy))

  11. TOPIC: ((methadone or buprenorphine or subutex or suboxone))

  12. #11 OR #10

  13. TOPIC: ("Hepatitis C")

  14. TOPIC: ("Hep C")

  15. TOPIC: (HCV)

  16. #15 OR #14 OR #13

  17. #12 OR #6

  18. #17 AND #16 AND #9

Indexes=SCI‐EXPANDED, SSCI, A&HCI Timespan=All years

Appendix 2. Search strategies to identify longitudinal studies

MEDLINE, PsycINFO & Global Health (Ovid)

  1. Substance Abuse, Intravenous/

  2. (substance$ or drug$).ab,ti.

  3. (abuse$ or depend$ or use$ or misus$ or addict$).ab,ti.

  4. (inject$ or intravenous).ab,ti.

  5. 1 or (2 and 3) or (2 and 4)

  6. exp Hepatitis C/

  7. (hepatitis‐c or hcv).ab,ti.

  8. (HCV adj2 seroconvers$).ti,ab.

  9. (HCV adj2 transmission).ti,ab.

  10. or/6‐9

  11. exp Cohort Studies/

  12. exp Longitudinal Studies/

  13. (prospective or longitudinal or cohort).ti,ab.

  14. or/11‐13

  15. 5 and 10 and 14

  16. Animals/

  17. 15 not 16

Embase (embase.com)

'substance abuse'/exp OR ((substance* OR drug* OR opiate* OR opioid* OR heroin* OR morphin* OR morfin* OR narcot*) NEAR/6 (use* OR abus* OR misuse* OR addict* OR depend*)):ab,ti OR ((substance* OR drug*) NEAR/6 (inject* OR intravenous)):ab,ti AND ('hepatitis c'/exp OR 'hepatitis‐c':ab,ti OR 'hep c':ab,ti ORhcv:ab,ti) AND ('cohort analysis'/exp OR 'longitudinal study'/exp OR prospective:ab,ti OR longitudinal:ab,ti OR cohort:ab,ti)

CINAHL (EBSCO)

  1. (MH "Substance Abuse, Intravenous")

  2. TI ((substance* OR drug* OR opiate* OR opioid* OR heroin* OR morphin* OR morfin* OR narcot*) N6 (use* OR abus* OR misuse* OR addict* OR depend*))

  3. AB ((substance* OR drug* OR opiate* OR opioid* OR heroin* OR morphin* OR morfin* OR narcot*) N6 (use* OR abus* OR misuse* OR addict* OR depend*))

  4. TI ( substance* OR drug* ) AND TI ( inject* OR intravenous )

  5. AB( substance* OR drug* ) AND AB( inject* OR intravenous )

  6. S1 OR S2 OR S3 OR S4 OR S5

  7. (MH "Hepatitis C+")

  8. TI ( "hepatitis‐c" or "hep c" or hcv ) OR AB ( "hepatitis‐c" or "hep c" or hcv )

  9. S7 OR S8

  10. (MH "Prospective Studies+")

  11. TI ( prospective or longitudinal or cohort ) OR AB ( prospective or longitudinal or cohort )

  12. S10 OR S11

  13. S6 AND S9 AND S12

Web of Science (THOMSON REUTERS)

  1. TOPIC: (((substance* OR drug* OR opiate* OR opioid* OR heroin* OR morphin* OR morfin* OR narcot*) NEAR/6 (use* OR abus* OR misuse* OR addict* OR depend*)))

  2. TOPIC: ((substance* or drug) and (inject* or intravenous))

  3. #1 OR #2

  4. TOPIC: ("Hepatitis C")

  5. TOPIC: ("Hep C")

  6. TOPIC: (HCV)

  7. #4 OR #5 OR #6

  8. TOPIC: (prospective or longitudinal or cohort)

  9. #3 AND #7 AND #8

Indexes=SCI‐EXPANDED, SSCI, A&HCI Timespan=All years

Appendix 3. Criteria for risk of bias assessment for RCTs

Item

Judgment

Description

1. Random sequence generation (selection bias)

Low risk

The investigators describe a random component in the sequence generation process such as: random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimisation.

High risk

The investigators describe a non‐random component in the sequence generation process such as: odd or even date of birth; date (or day) of admission; hospital or clinic record number; alternation; judgment of the clinician; results of a laboratory test or a series of tests; availability of the intervention.

Unclear risk

Insufficient information about the sequence generation process to permit judgment of low or high risk

2. Allocation concealment (selection bias)

Low risk

Investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web‐based, and pharmacy‐controlled, randomisation); sequentially‐numbered drug containers of identical appearance; sequentially‐numbered, opaque, sealed envelopes.

High risk

Investigators enrolling participants could possibly foresee assignments because one of the following method was used: open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate safeguards (e.g. if envelopes were unsealed or non­opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.

Unclear risk

Insufficient information to permit judgment of low or high risk. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgment.

3. Blinding of participants and providers (performance bias)

Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding

Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken

High risk

No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding

Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding

Unclear risk

Insufficient information to permit judgment of low or high risk

4. Blinding of participants and providers (performance bias)

Subjective outcomes

Low risk

Blinding of participants and providers ensured and unlikely that the blinding could have been broken

High risk

No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding

Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding

Unclear risk

Insufficient information to permit judgment of low or high risk

5. Blinding of outcome assessor (detection bias)

Objective outcomes

Low risk

No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding

Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken

High risk

No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding

Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding

Unclear risk

Insufficient information to permit judgment of low or high risk

6.Blinding of outcome assessor (detection bias)

Subjective outcomes

Low risk

Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken

High risk

No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding

Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding

Unclear risk

Insufficient information to permit judgment of low or high risk

7. Incomplete outcome data (attrition bias)

For all outcomes except retention in treatment or drop out

Low risk

No missing outcome data

Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias)

Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups

For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically‐relevant impact on the intervention effect estimate

For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically‐relevant impact on observed effect size

Missing data have been imputed using appropriate methods

All randomised patients are reported/analysed in the group they were allocated to by randomisation irrespective of non‐compliance and co‐interventions (intention to treat)

High risk

Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups

For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate

For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size

'As‐treated' analysis done with substantial departure of the intervention received from that assigned at randomisation

Unclear risk

Insufficient information to permit judgment of low or high risk (e.g. number randomised not stated, no reasons for missing data provided; number of dropout not reported for each group)

8 Selective reporting (reporting bias)

Low risk

The study protocol is available and all of the study's pre‐specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre‐specified way

The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre‐specified (convincing text of this nature may be uncommon)

High risk

Not all of the study's pre‐specified primary outcomes have been reported

One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre‐specified

One or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);

One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis

The study report fails to include results for a key outcome that would be expected to have been reported for such a study

Unclear risk

Insufficient information to permit judgment of low or high risk

Appendix 4. Criteria for risk of bias assessment for observational studies

Domain

Judgment

Description

Bias due to confounding

Low risk (the study is comparable to a well‐performed randomised trial with regard to this domain)

No confounding expected

Moderate risk (the study is

sound for a non‐randomised study with regard to this domain but cannot be considered comparable to a well performed randomised trial)

Confounding expected, all known critically important confounding domains appropriately measured and adjusted for;

and

Reliability and validity of measurement of a critically important domains were sufficient that we do not expect serious residual confounding.

Serious risk (the study has some important problems)

At least one known critically important domain not appropriately measured, or not adjusted for;

or

Reliability or validity of measurement of a critically important domain was low enough that we expect serious residual confounding.

Critical risk (the study is too problematic to provide any useful evidence on the effects of intervention)

Confounding inherently not controllable, or use of negative controls strongly suggests unmeasured confounding

No information on which to base a judgment about risk of bias for this domain

No information on whether confounding might be present

Bias in selection of participants into the study

Low risk

All participants who would have been eligible for the target trial were included in the study and start of follow‐up and start of intervention coincide for all participants

Moderate risk

Selection into the study may have been related to intervention and outcome, but the authors used appropriate methods to adjust for the selection bias;

or

Start of follow‐up and start of intervention do not coincide for all participants, but the proportion of participants for which this was the case was too low to induce important bias; the authors used appropriate methods to adjust for the selection bias; or the review authors are confident that the rate (hazard) ratio for the effect of intervention remains constant over time.

Serious risk

Selection into the study was related to intervention and outcome;

or

Start of follow‐up and start of intervention do not coincide, and a potentially important amount of follow‐up time is missing from analyses, and the rate ratio is not constant over time.

Critical risk

Selection into the study was strongly related to intervention and outcome;

or

A substantial amount of follow‐up time is likely to be missing from analyses, and the rate ratio is not constant over time.

No information

No information is reported about selection of participants into the study or whether start of follow‐up and start of intervention coincide

Bias in measurement of interventions

Low risk

Intervention status is well defined and based solely on information collected at the time of intervention

Moderate risk

Intervention status is well defined but some aspects of the assignments of intervention status were determined retrospectively

Serious risk

Intervention status is not well defined, or major aspects of the assignments of intervention status were determined in a way that could have been affected by knowledge of the outcome

Critical risk

(Unusual) An extremely high amount of misclassification of intervention status, e.g. because of unusually strong recall biases

No information

No definition of intervention or no explanation of the source of information about intervention status

Bias due to departures from intended

interventions

Low risk

No bias due to departure from the intended intervention is expected, for example if both the intervention and comparator are implemented over a short time period, and subsequent interventions are part of routine medical care, or if the specified comparison relates to initiation of intervention regardless of whether it is continued

Moderate risk

Bias due to departure from the intended intervention is expected, and switches, co‐interventions, and some problems with intervention fidelity are appropriately measured and adjusted for in the analyses. Alternatively, most (but not all) departures from intended intervention reflect the natural course of events after initiation of intervention.

Serious risk

Switches in treatment, co‐interventions, or problems with implementation fidelity are apparent and are not adjusted for in the analyses.

Critical risk

Substantial departures from the intended intervention are present and are not adjusted for in the analysis.

No information

No information is reported on whether there is departure from the intended intervention.

Bias due to missing data

Low risk

Data were reasonably complete;

or

Proportions and reasons of missing participants were similar across intervention groups;

or

Analyses that addressed missing data are likely to have removed any risk of bias.

Moderate risk

Proportions of missing participants differ across

interventions or reasons for missingness differ minimally across interventions;

and

Missing data were not addressed in the analysis.

Serious risk

Proportions of missing participants differ substantially across interventions or reasons for missingness differ substantially across interventions;

and

Missing data were addressed inappropriately in the analysis;

or

The nature of the missing data means that the risk of

bias cannot be removed through appropriate analysis.

Critical risk

(Unusual) There were critical differences between

interventions in participants with missing data that were not, or could not, be addressed through appropriate analysis.

No information

No information is reported about missing data or the

potential for data to be missing

Bias in measurement of outcomes

Low risk

The methods of outcome assessment were comparable across intervention groups;

and

The outcome measure was unlikely to be influenced by knowledge of the intervention received by study participants (i.e. is objective) or the outcome assessors were unaware of the intervention received by study participants;

and

Any error in measuring the outcome is unrelated to

intervention status.

Moderate risk

The methods of outcome assessment were comparable across intervention groups;

and

The outcome measure is only minimally influenced by knowledge of the intervention received by study

participants;

and

Any error in measuring the outcome is only minimally related to intervention status.

Serious risk

The methods of outcome assessment were not comparable across intervention groups;

or

The outcome measure was subjective (i.e. likely to be

influenced by knowledge of the intervention received by study participants) and was assessed by outcome assessors aware of the intervention received by study participants;

or

Error in measuring the outcome was related to intervention status.

Critical risk

The methods of outcome assessment were so different that they cannot reasonably be compared across intervention groups.

No information

No information is reported about the methods of outcome assessment.

Bias in selection of the reported result

Low risk

There is clear evidence (usually through examination of a pre‐registered protocol or statistical analysis plan) that all reported results correspond to all intended outcomes, analyses and sub‐cohorts.

Moderate risk

The outcome measurements and analyses are consistent with an a priori plan; or are clearly defined, and internally and externally consistent;

and

There is no indication of selection of the reported analysis from among multiple analyses;

and

There is no indication of selection of the cohort or subgroups for analysis and reporting on the basis of the results.

Serious risk

Outcome measurements or analyses are internally or

externally inconsistent;

or

There is a high risk of selective reporting from among

multiple analyses;

or

The cohort or subgroup is selected from a larger study for analysis and appears to be reported on the basis of the results.

Critical risk

There is evidence or strong suspicion of selective reporting of results, and the unreported results are likely to be substantially different from the reported results.

No information

There is too little information to make a judgment, for example if only an abstract is available for the study.

Overall judgment about risk of bias

Low risk

The study is judged to be at low risk of bias for all domains.

Moderate risk

The study is judged to be at low or moderate risk of bias for all domains.

Serious risk

The study is judged to be at serious risk of bias in at least one domain, but not at critical risk of bias in any domain.

Critical risk

The study is judged to be at critical risk of bias in at least one domain.

No information

There is no clear indication that the study is at

serious or critical risk of bias and there is a lack of information in one or more key domains of bias (a judgment is required for this).

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Forest plot of comparison: 1 Current OST versus no OST, outcome: 1.1 HCV incidence adjusted analyses by region.
Figuras y tablas -
Figure 2

Forest plot of comparison: 1 Current OST versus no OST, outcome: 1.1 HCV incidence adjusted analyses by region.

Funnel plot of comparison: 1 Current OST versus no OST, outcome: 1.1 HCV incidence adjusted analyses by region.
Figuras y tablas -
Figure 3

Funnel plot of comparison: 1 Current OST versus no OST, outcome: 1.1 HCV incidence adjusted analyses by region.

Forest plot of comparison: 2 High NSP coverage versus no/low NSP coverage, outcome: 2.1 HCV incidence adjusted analyses by region.
Figuras y tablas -
Figure 4

Forest plot of comparison: 2 High NSP coverage versus no/low NSP coverage, outcome: 2.1 HCV incidence adjusted analyses by region.

Forest plot of comparison: 4 Combined OST and high/low NSP versus no OST and low/no NSP, outcome: 4.1 HCV incidence adjusted analyses.
Figuras y tablas -
Figure 5

Forest plot of comparison: 4 Combined OST and high/low NSP versus no OST and low/no NSP, outcome: 4.1 HCV incidence adjusted analyses.

Comparison 1 Current OST versus no OST, Outcome 1 HCV incidence adjusted analyses by region.
Figuras y tablas -
Analysis 1.1

Comparison 1 Current OST versus no OST, Outcome 1 HCV incidence adjusted analyses by region.

Comparison 1 Current OST versus no OST, Outcome 2 HCV incidence adjusted analysis by study design.
Figuras y tablas -
Analysis 1.2

Comparison 1 Current OST versus no OST, Outcome 2 HCV incidence adjusted analysis by study design.

Comparison 1 Current OST versus no OST, Outcome 3 HCV incidence unadjusted analyses by different modes of OST provision.
Figuras y tablas -
Analysis 1.3

Comparison 1 Current OST versus no OST, Outcome 3 HCV incidence unadjusted analyses by different modes of OST provision.

Comparison 2 Sensitivity analysis: OST versus no OST, adjusted analyses excluding unpublished datasets, Outcome 1 HCV incidence.
Figuras y tablas -
Analysis 2.1

Comparison 2 Sensitivity analysis: OST versus no OST, adjusted analyses excluding unpublished datasets, Outcome 1 HCV incidence.

Comparison 3 Sensitivity analysis: OST versus no OST, adjusted analyses excluding studies at critical risk of bias, Outcome 1 HCV incidence.
Figuras y tablas -
Analysis 3.1

Comparison 3 Sensitivity analysis: OST versus no OST, adjusted analyses excluding studies at critical risk of bias, Outcome 1 HCV incidence.

Comparison 4 Sensitivity analysis: OST versus no OST, adjusted analyses excluding cross‐sectional studies, Outcome 1 HCV incidence.
Figuras y tablas -
Analysis 4.1

Comparison 4 Sensitivity analysis: OST versus no OST, adjusted analyses excluding cross‐sectional studies, Outcome 1 HCV incidence.

Comparison 5 OST versus no OST, unadjusted analysis, Outcome 1 HCV incidence.
Figuras y tablas -
Analysis 5.1

Comparison 5 OST versus no OST, unadjusted analysis, Outcome 1 HCV incidence.

Comparison 6 High NSP coverage versus no/low NSP coverage, Outcome 1 HCV incidence adjusted analyses by region.
Figuras y tablas -
Analysis 6.1

Comparison 6 High NSP coverage versus no/low NSP coverage, Outcome 1 HCV incidence adjusted analyses by region.

Comparison 6 High NSP coverage versus no/low NSP coverage, Outcome 2 HCV incidence adjusted analyses by study design.
Figuras y tablas -
Analysis 6.2

Comparison 6 High NSP coverage versus no/low NSP coverage, Outcome 2 HCV incidence adjusted analyses by study design.

Comparison 7 Sensitivity analysis: high NSP versus low/no NSP, excluding unpublished data, Outcome 1 HCV incidence.
Figuras y tablas -
Analysis 7.1

Comparison 7 Sensitivity analysis: high NSP versus low/no NSP, excluding unpublished data, Outcome 1 HCV incidence.

Comparison 8 Sensitivity analysis: high NSP versus low/no NSP, excluding cross‐sectional surveys, Outcome 1 HCV incidence.
Figuras y tablas -
Analysis 8.1

Comparison 8 Sensitivity analysis: high NSP versus low/no NSP, excluding cross‐sectional surveys, Outcome 1 HCV incidence.

Comparison 9 High NSP coverage versus low/no coverage, unadjusted estimates, Outcome 1 HCV incidence.
Figuras y tablas -
Analysis 9.1

Comparison 9 High NSP coverage versus low/no coverage, unadjusted estimates, Outcome 1 HCV incidence.

Comparison 10 Low NSP coverage versus no coverage, Outcome 1 HCV incidence, adjusted analyses.
Figuras y tablas -
Analysis 10.1

Comparison 10 Low NSP coverage versus no coverage, Outcome 1 HCV incidence, adjusted analyses.

Comparison 11 Low NSP coverage versus no NSP, unadjusted analysis, Outcome 1 HCV incidence.
Figuras y tablas -
Analysis 11.1

Comparison 11 Low NSP coverage versus no NSP, unadjusted analysis, Outcome 1 HCV incidence.

Comparison 12 Combined OST and high/low NSP versus no OST and low/no NSP, Outcome 1 HCV incidence adjusted analyses.
Figuras y tablas -
Analysis 12.1

Comparison 12 Combined OST and high/low NSP versus no OST and low/no NSP, Outcome 1 HCV incidence adjusted analyses.

Comparison 12 Combined OST and high/low NSP versus no OST and low/no NSP, Outcome 2 HCV incidence unadjusted analyses.
Figuras y tablas -
Analysis 12.2

Comparison 12 Combined OST and high/low NSP versus no OST and low/no NSP, Outcome 2 HCV incidence unadjusted analyses.

Summary of findings for the main comparison. Current OST versus no OST for people who inject drugs

Current OST versus no OST

Patient or population: people who inject drugs
Settings: outpatient
Intervention: current OST versus no OST

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Assumed risk

Corresponding risk

No OST

Current OST

HCV incidence adjusted analyses
number of HCV seroconversion
Follow‐up: mean 440.5 person‐years

RR 0.50

(0.40 to 0.63)

6361
(12 studies)

⊕⊕⊝⊝
Lowa,b

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OST: opioid substitution therapy; RR: risk ratio.

GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

aDowngraded one level due to overall moderate risk of bias in 2 studies, overall serious risk of bias in 6 studies, 2 studies at overall critical risk of bias in 2 studies; not enough information to make judgment in 2 studies.
bUpgraded one level due to large magnitude of the effect: RR: 0.5.

Figuras y tablas -
Summary of findings for the main comparison. Current OST versus no OST for people who inject drugs
Summary of findings 2. High NSP coverage versus no/low NSP coverage for people who inject drugs

High NSP coverage versus no/low NSP coverage

Patient or population: people who inject drugs
Settings: outpatients
Intervention: high NSP coverage versus no/low NSP coverage

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Assumed risk

Corresponding risk

No/low NSP coverage

High NSP coverage

HCV incidence adjusted analyses
number of HCV seroconversion
Follow‐up: mean 269 person‐years

RR: 0.79 (0.39 to 1.61)

3530
(5 studies)

⊕⊝⊝⊝
Very lowa,b

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; NSP: needle syringe programmes; RR: risk ratio.

GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

aDowngraded one level due to serious overall risk of bias in all the studies.
bDowngraded one level due to significant heterogeneity: I2: 77%.

Figuras y tablas -
Summary of findings 2. High NSP coverage versus no/low NSP coverage for people who inject drugs
Summary of findings 3. Combined OST and high NSP versus no OST and low/no NSP for people who inject drugs

Combined OST and highNSP versus no OST and low/no NSP

Patient or population: people who inject drugs
Settings: outpatients
Intervention: Combined OST and high/low NSP versus no OST and low/no NSP

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Assumed risk

Corresponding risk

No OST and low/no NSP

Combined OST and high NSP

HCV incidence adjusted analyses
number of HCV seroconversions
Follow‐up: mean 356 person‐years

RR: 0.26 (0.07 to 0.89)

3241
(3 studies)

⊕⊕⊕⊝

Lowa,b

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; NSP: needle syringe programmes; OST: opioid substitution therapy; RR: Risk ratio.

GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

aDowngraded one level due to serious overall risk of bias in all studies.
bUpgraded one level due to very large magnitude of the effect: RR: 0.26.

Figuras y tablas -
Summary of findings 3. Combined OST and high NSP versus no OST and low/no NSP for people who inject drugs
Table 1. Risk of bias of included studies

Study

Confounding

Selection bias

Measurement of interventions

Departures from intended interventions

Missing data

Measurement of outcomes

Selection of reported result

Overall risk of bias

Aitken 2015 [pers comm]

Critical

Critical

Serious

No info

Critical

Low

No info

Critical

Bruneau 2015 [pers comm]

Moderate

Serious

Moderate

No info

No info

Low

Low

Serious

Craine 2009

Serious

Serious

Serious

No info

Serious

Low

Low

Serious

Crofts 1997

Critical

Serious

Low

No info

Serious

Serious

Low

Critical

Hagan 1995

Serious

Serious

Serious

No info

Low

Low

Low

Serious

Hagan 1999

Moderate

Serious

Low

No info

Low

Low

Low

Serious

Holtzman 2009

Serious

Serious

Moderate

No info

No info

Low

Low

Serious

Hope 2011

Moderate

Moderate

Serious

No info

Low

Low

Low

Serious

Hope 2015 [pers comm]

Moderate

Moderate

Serious

No info

No info

Low

Low

Serious

Judd 2015 [pers comm]

Moderate

Critical

Critical

No info

Critical

Low

Low

Critical

Lucidarme 2004

Moderate

Serious

Serious

No info

Serious

Low

Low

Serious

Maher 2015

Moderate

Serious

Serious

No info

No info

Low

Low

Serious

Mehta 2015 [pers comm]

Moderate

No info

No info

No info

No info

Low

Low

No info

Nolan 2014

Serious

Serious

Moderate

No info

Low

Low

Low

Serious

Page 2015 [pers comm]

Moderate

No info

No info

No info

No info

Low

Low

No info

Palmateer 2014a

Serious

Serious

Moderate

No info

Serious

Low

Low

Serious

Patrick 2001

Serious

Moderate

Serious

No info

Serious

Low

Low

Serious

Rezza 1996

Serious

Low

Serious

No info

Critical

Low

Low

Critical

Roy 2007

Serious

Serious

Serious

No info

Critical

Low

Low

Critical

Ruan 2007

Critical

Critical

Serious

No info

Serious

Low

Low

Critical

Spittal 2012

Serious

Serious

Moderate

No info

Low

Low

Low

Serious

Thiede 2000

Moderate

Moderate

Low

No info

Low

Low

Low

Moderate

Thorpe 2002

Serious

Serious

Serious

No info

Moderate

Low

Low

Serious

Tsui 2014

Moderate

Moderate

Low

No info

Moderate

Low

Low

Moderate

Vallejo 2015

Serious

Serious

Low

No info

Serious

Low

Low

Serious

Van Beek 1998

Critical

Serious

Serious

No info

Critical

Low

Low

Critical

Van Den Berg 2007

Serious

Serious

Moderate

No info

Serious

Low

Low

Serious

White 2014

Moderate

Serious

Moderate

No info

No info

Low

Low

Serious

Figuras y tablas -
Table 1. Risk of bias of included studies
Table 2. Univariable meta‐regression analysis for studies measuring impact of current use of OST on HCV incidence

Variable

Studies

Univariable rate ratio (95% CI)

Ratio of rate ratios

(95% CI)

P value

Tau2

Geographic region

Europe

8

0.51 (0.37‐0.70)

1.0 (ref)

Australia

5

0.55 (0.28‐1.11)

1.12 (0.52‐2.41)

North America

6

0.69 (0.44‐1.08)

1.42 (0.73‐2.78)

0.53

0.10

Site of recruitment

Service attenders

12

0.67 (0.49‐0.92)

1.0 (ref)

Community

7

0.49 (0.33‐0.73)

0.73 (0.42‐1.27)

0.256

0.06

Study design

Cross‐sectional

4

0.51 (0.31‐0.85)

1.0

Prospective cohort

15

0.58 (0.43‐0.77)

1.12 (0.48‐2.61)

0.784

0.10

Females

17

1.59 (1.13‐2.29)

0.01

0.04

Prison experience

11

1.057 (0.61‐1.79)

0.821

0.43

Experience of homelessness

12

1.08 (0.83‐1.40)

0.521

0.23

Injection of stimulants

12

0.89 (0.65‐1.22)

0.373

0.17

Daily injection

7

0.88 (0.64‐1.22)

0.373

0.17

CI: confidence interval; HCV: hepatitis C virus; OST: opioid substitution therapy.

Figuras y tablas -
Table 2. Univariable meta‐regression analysis for studies measuring impact of current use of OST on HCV incidence
Table 3. Univariable meta‐regression analysis for studies measuring impact of high NSP coverage on HCV incidence

Variable

Studies

Univariable rate ratio (95%CI)

Ratio of rate ratios (95%CI)

P value

Tau2

Geographic region

Europe

5

0.44 (0.24‐0.80)

1.0 (Ref)

North America

3

1.58 (0.57‐4.42)

3.73 (0.95‐14.7)

0.057

0.41

Recruitment site

Service attenders

3

0.67 (0.28‐1.59)

1.0 (Ref)

Community

5

0.82 (0.29‐2.32)

0.76(0.12‐4.88)

0.74

0.89

Study design

Cross‐sectional survey

3

0.34 (0.16‐0.75)

1.0 (Ref)

Prospective cohort

4

1.26 (0.55‐2.93)

3.53 (0.78‐15.86)

0.087

0.48

Females

7

2.97(0.38‐23.1)

0.24

0.87

Prison experience

3

NA

Experience of homelessness

6

1.01 (0.38‐2.67)

0.976

1.53

Injection of stimulants

7

1.08 (0.47‐2.51)

0.827

1.15

Daily injection

5

3.66 (0.22‐61.3)

0.239

1.15

CI: confidence interval; HCV: hepatitis C virus; NSP: needle syringe programmes.

Figuras y tablas -
Table 3. Univariable meta‐regression analysis for studies measuring impact of high NSP coverage on HCV incidence
Comparison 1. Current OST versus no OST

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 HCV incidence adjusted analyses by region Show forest plot

12

6361

Risk Ratio (Random, 95% CI)

0.50 [0.40, 0.63]

1.1 North America

5

2245

Risk Ratio (Random, 95% CI)

0.57 [0.42, 0.76]

1.2 Europe

5

3494

Risk Ratio (Random, 95% CI)

0.43 [0.27, 0.68]

1.3 Australia

2

622

Risk Ratio (Random, 95% CI)

0.42 [0.25, 0.72]

2 HCV incidence adjusted analysis by study design Show forest plot

12

6361

Risk Ratio (Random, 95% CI)

0.50 [0.40, 0.63]

2.1 Prospective cohort

10

3467

Risk Ratio (Random, 95% CI)

0.51 [0.40, 0.65]

2.2 Cross‐sectional surveys

2

2894

Risk Ratio (Random, 95% CI)

0.46 [0.23, 0.89]

3 HCV incidence unadjusted analyses by different modes of OST provision Show forest plot

9

Risk Ratio (Random, 95% CI)

Subtotals only

3.1 Ever used OST

3

375

Risk Ratio (Random, 95% CI)

0.81 [0.52, 1.27]

3.2 Interrupted OST use

3

1157

Risk Ratio (Random, 95% CI)

0.80 [0.57, 1.10]

3.3 Detoxification

1

552

Risk Ratio (Random, 95% CI)

1.45 [0.79, 2.66]

3.4 High dose

2

453

Risk Ratio (Random, 95% CI)

0.52 [0.29, 0.94]

3.5 Low dose

2

453

Risk Ratio (Random, 95% CI)

0.85 [0.44, 1.65]

Figuras y tablas -
Comparison 1. Current OST versus no OST
Comparison 2. Sensitivity analysis: OST versus no OST, adjusted analyses excluding unpublished datasets

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 HCV incidence Show forest plot

8

5235

Risk Ratio (Random, 95% CI)

0.42 [0.31, 0.58]

Figuras y tablas -
Comparison 2. Sensitivity analysis: OST versus no OST, adjusted analyses excluding unpublished datasets
Comparison 3. Sensitivity analysis: OST versus no OST, adjusted analyses excluding studies at critical risk of bias

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 HCV incidence Show forest plot

9

5782

Risk Ratio (Random, 95% CI)

0.51 [0.40, 0.64]

Figuras y tablas -
Comparison 3. Sensitivity analysis: OST versus no OST, adjusted analyses excluding studies at critical risk of bias
Comparison 4. Sensitivity analysis: OST versus no OST, adjusted analyses excluding cross‐sectional studies

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 HCV incidence Show forest plot

10

3467

Risk Ratio (Random, 95% CI)

0.51 [0.40, 0.65]

Figuras y tablas -
Comparison 4. Sensitivity analysis: OST versus no OST, adjusted analyses excluding cross‐sectional studies
Comparison 5. OST versus no OST, unadjusted analysis

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 HCV incidence Show forest plot

16

9499

Risk Ratio (Random, 95% CI)

0.57 [0.45, 0.73]

Figuras y tablas -
Comparison 5. OST versus no OST, unadjusted analysis
Comparison 6. High NSP coverage versus no/low NSP coverage

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 HCV incidence adjusted analyses by region Show forest plot

5

3530

Risk Ratio (Random, 95% CI)

0.79 [0.39, 1.61]

1.1 North America

3

627

Risk Ratio (Random, 95% CI)

1.25 [0.63, 2.46]

1.2 Europe

2

2903

Risk Ratio (Random, 95% CI)

0.24 [0.09, 0.62]

2 HCV incidence adjusted analyses by study design Show forest plot

5

3530

Risk Ratio (Random, 95% CI)

0.95 [0.50, 1.82]

2.1 Prospective cohorts

3

627

Risk Ratio (Random, 95% CI)

1.44 [1.01, 2.05]

2.2 Cross‐sectional surveys

2

2903

Risk Ratio (Random, 95% CI)

0.24 [0.09, 0.62]

Figuras y tablas -
Comparison 6. High NSP coverage versus no/low NSP coverage
Comparison 7. Sensitivity analysis: high NSP versus low/no NSP, excluding unpublished data

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 HCV incidence Show forest plot

4

3245

Risk Ratio (Random, 95% CI)

0.77 [0.28, 2.13]

Figuras y tablas -
Comparison 7. Sensitivity analysis: high NSP versus low/no NSP, excluding unpublished data
Comparison 8. Sensitivity analysis: high NSP versus low/no NSP, excluding cross‐sectional surveys

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 HCV incidence Show forest plot

3

627

Risk Ratio (Random, 95% CI)

1.25 [0.63, 2.46]

Figuras y tablas -
Comparison 8. Sensitivity analysis: high NSP versus low/no NSP, excluding cross‐sectional surveys
Comparison 9. High NSP coverage versus low/no coverage, unadjusted estimates

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 HCV incidence Show forest plot

7

6455

Risk Ratio (Random, 95% CI)

0.78 [0.39, 1.55]

Figuras y tablas -
Comparison 9. High NSP coverage versus low/no coverage, unadjusted estimates
Comparison 10. Low NSP coverage versus no coverage

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 HCV incidence, adjusted analyses Show forest plot

6

2765

Risk Ratio (Random, 95% CI)

1.43 [0.82, 2.49]

Figuras y tablas -
Comparison 10. Low NSP coverage versus no coverage
Comparison 11. Low NSP coverage versus no NSP, unadjusted analysis

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 HCV incidence Show forest plot

9

3242

Risk Ratio (Random, 95% CI)

1.41 [0.95, 2.09]

Figuras y tablas -
Comparison 11. Low NSP coverage versus no NSP, unadjusted analysis
Comparison 12. Combined OST and high/low NSP versus no OST and low/no NSP

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 HCV incidence adjusted analyses Show forest plot

3

6197

Risk Ratio (Random, 95% CI)

0.45 [0.22, 0.94]

1.1 High NSP coverage

3

3241

Risk Ratio (Random, 95% CI)

0.26 [0.07, 0.89]

1.2 Low NSP coverage

2

2956

Risk Ratio (Random, 95% CI)

0.87 [0.44, 1.68]

2 HCV incidence unadjusted analyses Show forest plot

4

6427

Risk Ratio (Random, 95% CI)

0.47 [0.27, 0.80]

2.1 Combined OST and high NSP versus no OST and low/no NSP

4

3356

Risk Ratio (Random, 95% CI)

0.29 [0.13, 0.65]

2.2 Combined OST and low NSP versus no OST and low/no NSP

3

3071

Risk Ratio (Random, 95% CI)

0.76 [0.44, 1.33]

Figuras y tablas -
Comparison 12. Combined OST and high/low NSP versus no OST and low/no NSP